Nagase Hiroyuki
Rinsho Byori. 2014 Dec;62(12):1226-33.
The measurement of FeNO (fractional nitric oxide concentration in exhaled breath) is a noninvasive method to assess airway inflammation. The elevated level of FeNO in asthma patients was first reported in 1993, and measurement has been covered by insurance in Japan since April 2013. NO is generated through the conversion of L-arginine to L-citrulline by the action of nitric oxide synthase (NOS) and iNOS is highly expressed in asthmatic airways. FeNO is expiratory flow-ependent, and measurement at 50 mL/s is recommended. As a nitrate-rich diet and the contamination of nasal NO increase, and smoking and spirometry decrease FeNO, these factors should be avoided or taken into account when measuring FeNO. For clinical application, FeNO may be used for the diagnosis or as a guide to treat asthma. Although FeNO correlates well with eosinophilic airway inflammation, it is not present in all asthma patients, and eosinophilic bronchitis or a part of COPD also shows eosinophilic inflammation. Thus, FeNO may be used as an adjunct for asthma diagnosis, and in ATS guideline, it is recommended to use FeNO for the diagnosis of eosinophilic airway inflammation and determining the likelihood of responsiveness to steroids. Several studies attempted to use FeNO to determine the dose of ICS (inhaled corticosteroids) and compared FeNO with traditional guideline-based management. The results were inconsistent, and the Cochrane review found that FeNO-based treatment did not lead to a reduction in the ICS dose or improved asthma outcomes. Nevertheless, a study of a pregnant woman showed reduced exacerbations with a refined algorithm, and further research will shed light on the appropriate application of FeNO measurement for asthma management. In this paper, the mechanism of NO generation, background and method of FeNO measurement, and clinical application will be reviewed and an outline of the official ATS clinical practice guideline will be introduced.
呼出气体中一氧化氮分数浓度(FeNO)的测量是评估气道炎症的一种非侵入性方法。1993年首次报道了哮喘患者FeNO水平升高,自2013年4月起日本已将该测量纳入医保范围。一氧化氮(NO)是通过一氧化氮合酶(NOS)的作用将L-精氨酸转化为L-瓜氨酸而生成的,诱导型一氧化氮合酶(iNOS)在哮喘气道中高度表达。FeNO与呼气流量有关,建议在50 mL/s的流量下进行测量。由于富含硝酸盐的饮食和鼻腔NO的污染会使FeNO升高,而吸烟和肺活量测定会使FeNO降低,因此在测量FeNO时应避免或考虑这些因素。在临床应用中,FeNO可用于哮喘的诊断或作为治疗的指导。虽然FeNO与嗜酸性粒细胞性气道炎症密切相关,但并非所有哮喘患者都有FeNO升高,嗜酸性粒细胞性支气管炎或慢性阻塞性肺疾病(COPD)的一部分也表现为嗜酸性粒细胞炎症。因此,FeNO可作为哮喘诊断的辅助手段,美国胸科学会(ATS)指南建议使用FeNO诊断嗜酸性粒细胞性气道炎症并确定对类固醇反应的可能性。多项研究试图用FeNO来确定吸入性糖皮质激素(ICS)的剂量,并将FeNO与基于传统指南的管理方法进行比较。结果并不一致,Cochrane综述发现基于FeNO的治疗并未导致ICS剂量减少或改善哮喘预后。尽管如此,一项针对孕妇的研究表明,采用优化算法可减少病情加重,进一步的研究将阐明FeNO测量在哮喘管理中的适当应用。本文将对NO生成的机制、FeNO测量的背景和方法以及临床应用进行综述,并介绍ATS官方临床实践指南的概要。